Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028☆
Section snippets
Background
Ovarian cancer is the seventh most common cancer in women worldwide (sixth in the United States [1]) and ranks 18th overall. Of 239,000 patients who received diagnoses in 2012, almost two thirds (64%) died of the disease [2], largely because symptoms are vague and nonspecific and appear only when the disease is advanced and because effective screening strategies are lacking [3].
First-line treatment options include cytoreductive surgery followed by carboplatin plus paclitaxel or docetaxel [3].
Study design and patient population
KEYNOTE-028 is a nonrandomized (open-label), multicohort, phase Ib trial of pembrolizumab in patients with PD-L1–positive advanced solid tumors. Key eligibility criteria for the present cohort were age ≥18 years; advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of previous therapy (or disease for which no standard therapy exists or therapy is not considered appropriate by the patient and treating physician), measurable disease based on Response Evaluation
Baseline patient characteristics
Of 90 screened patients with ovarian cancer, 26 had PD-L1–positive disease and were enrolled (Supplemental Fig. 1). The median age of this cohort was 57.5 years (range, 44 to 75 years). More than one third (38.5%) presented initially with metastatic disease, and more than half (n = 15; 58%) previously received more than three lines of therapy for recurrent/metastatic disease; ten patients (38.5%) previously received at least five lines (Table 1). Consistent with NCCN guidelines [3], all
Discussion
The high rate of relapse or chemotherapy resistance after first-line treatment of ovarian cancer and the diminishing responses to currently recommended second-line or subsequent therapies [[3], [4], [5]] highlight an urgent need for an effective therapeutic strategy in this patient population. The role of PD-L1 selection for pembrolizumab in ovarian cancer has not been explored; however, the established success of pembrolizumab for the treatment of certain PD-L1–positive malignancies [[28], [29]
Acknowledgments
We thank the patients, investigators, and trial site personnel for their contributions to the study. We also thank Roger Danscy and Reshma Rangwala (employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA, at the time of this analysis) for contributions to the development of the analysis. Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, Jacqueline Kolston, PhD, and the ApotheCom pembrolizumab team (Yardley, PA, USA). This
Role of the funding source
Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA. This trial was designed by Merck representatives and academic advisors. Data were analyzed and interpreted by authors and representatives of the sponsor. Data were collected by investigators and site personnel and analyzed and interpreted by authors and Merck representatives. All authors had access to the data. Medical writing and editorial assistance was provided by
Data availability
Merck & Co., Inc.'s data sharing policy, including restrictions, is available at http://engagezone.merck.com/ds_documentation.php. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to [email protected].
Authors' disclosures of potential conflicts of interest
Andrea Varga: Principal/sub-Investigator of Clinical Trials - Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis,
Author contributions
Conception and design: Patrick A. Ott, Janice M. Mehnert.
Collection and assembly of data: Dominique Berton-Rigaud, Patrick A. Ott, Janice M. Mehnert, Anne Morosky.
Data analysis and interpretation: Andrea Varga, Patrick A. Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Daniela Matei, Anne Morosky, Ping Yang, Jane Ruman.
Manuscript writing: All authors.
Final approval of manuscript: All authors.
Accountable for all aspects of the work: All authors.
Provision of study materials: Daniela Matei,
References (41)
- et al.
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
Gynecol. Oncol.
(2016) - et al.
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Lancet Oncol.
(2017) - et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Lancet
(2016) - et al.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Ann. Oncol.
(2016) - et al.
Cancer statistics, 2017
CA Cancer J. Clin.
(2017) - et al.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Int. J. Cancer
(2015) - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Ovarian Cancer Including...
- et al.
Update on first-line treatment of advanced ovarian carcinoma
Int. J. Women's Health
(2013) - et al.
Management strategies for recurrent platinum-resistant ovarian cancer
Drugs
(2011) - et al.
Second-line treatment of ovarian cancer
Oncologist
(2000)
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Med. Oncol.
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
N. Engl. J. Med.
Immunity and immune suppression in human ovarian cancer
Immunotherapy
Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma
Cancer Investig.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Nat. Med.
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
Clin. Cancer Res.
The blockade of immune checkpoints in cancer immunotherapy
Nat. Rev. Cancer
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Proc. Natl. Acad. Sci. U. S. A.
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Proc. Natl. Acad. Sci. U. S. A.
The PD-1 pathway in tolerance and autoimmunity
Immunol. Rev.
Cited by (193)
Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer
2024, Critical Reviews in Oncology/HematologyPD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
2023, Drug Discovery TodayMass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
2023, Molecular and Cellular Proteomics
- ☆
Clinical trial information: NCT02054806.